Xiangxue Pharmaceutical (300147.SZ): A projected loss of 0.5996 billion yuan to -0.8624 billion yuan for the year 2024.

On January 15, Gu Longhui reported that Xiangxue Pharmaceutical (300147.SZ) announced its performance forecast for 2024. The net income attributable to shareholders of the listed company is expected to be a loss of 0.5996 billion to 0.8624 billion yuan, compared to a loss of 388.96 million yuan in the same period last year. The net income after deducting non-recurring gains and losses is expected to be a loss of 0.571 billion to 0.834 billion yuan, compared to a loss of 344.46 million yuan in the same period last year. The revenue is expected to be 1.613 billion to 2.013 billion yuan, while the revenue after deductions is expected to be 1.586 billion to 1.986 billion yuan. In 2024, the company will focus on its development strategy and annual operational goals through

Gelonghui FinanceJan 15 17:54

Xiangxue Pharmaceuticals: 2024 Annual Results Forecast

SZSIJan 15 17:46 · Announcements

A-shares flu Concept stocks are pulling back: Xiangxue Pharmaceutical has fallen over 7%, while Shandong Lukang Pharmaceutical briefly dropped 4%.

On January 7, Gelonghui reported that the flu Concept stocks, which had previously surged, collectively adjusted. Among them, Xiangxue Pharmaceutical decreased by over 7%, Apeloa Pharmaceutical and Shanghai Kaibao Pharmaceutical fell by over 5%, while Guilin Layn Natural Ingredients Corp., Zhejiang Hisun Pharmaceutical, Shijiazhuang Yiling Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical saw declines of over 2%. Shandong Lukang Pharmaceutical opened high and at one point fell to 4%, previously recording two consecutive trading limit ups.

Gelonghui FinanceJan 7 09:47

A-shares show unusual activity丨Traditional Chinese Medicine stocks all rose, with Guangdong Zhongsheng Pharmaceutical and several other stocks hitting the daily limit, as the State Council emphasized increasing support for the research and innovation of T

On January 6, in the A-share market, the Traditional Chinese Medicine Sector rose against the trend, with Datang Pharmaceutical rising nearly 19%, Shanghai Kaibao Pharmaceutical rising over 16%, Xiangxue Pharmaceutical rising over 14%, Henan Taloph Pharmaceutical Stock, Shijiazhuang Yiling Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Guangdong Zhongsheng Pharmaceutical hitting the 10% limit up, Shanghai Shenqi Pharmaceutical Investment Management rising 9%, Jinghua Pharmaceutical Group, Tianjin Chase Sun Pharmaceutical, and Jiangxi Wannianqing Cement rising over 8%, Guizhou Sanli Pharmaceutical Co.,Ltd., Biovalley, and Guizhou Xinbang Pharmaceutical rising over 7%, Shandong Wohua Pharmaceutical and Sunflower Pharmaceutical Group rising over 6%, Zhejiang Xinguang Pharmaceutical, Oukang Pharmaceutical, Gansu Longshenrongfa Pharmaceutical Industry, and Guilin Sanjin Pharmaceutical rising over 5%, Guiyang Xintian Pharmaceutical, Zhejiang Wecome Pharmaceutical, Chongqing Taiji Industry, and Hubei Jumpca

Gelonghui FinanceJan 6 15:20

Express News | Xiangxue Pharmaceutical: Subsidiary Guangdong Xiangxue Pharmaceutical intends to transfer 92% equity of Shanxi Xiangxue Medicine for 30.728 million yuan.

BreakingsNov 22, 2024 17:51

Xiangxue Pharmaceutical (300147.SZ): TAEST16001 injection is currently in Phase II clinical stage.

Gelonghui November 6th | xiangxue pharmaceutical (300147.SZ) stated on the investor interaction platform that the TAEST16001 injection is currently in Phase II clinical stage, and the progress of research and development will be disclosed to the public in the form of announcements based on clinical conditions and information disclosure rules.

Gelonghui FinanceNov 6, 2024 15:56